Kyverna Therapeutics, Inc. KYTX Accrued License Expense Related Party
Accrued License Expense Related Party at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept kytx:AccruedLicenseExpenseRelatedParty.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s accrued license expense related party.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s accrued license expense related party?
- Kyverna Therapeutics, Inc. (KYTX) reported accrued license expense related party of $3.75M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s accrued license expense related party changed year-over-year?
- Kyverna Therapeutics, Inc.'s accrued license expense related party decreased by 40.0% year-over-year, from $6.25M to $3.75M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s accrued license expense related party?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s accrued license expense related party has grown at a -22.5% compound annual growth rate (CAGR), from $6.25M to $3.75M.
- What does accrued license expense related party mean?
- This represents the outstanding financial obligations owed to related parties for the acquisition or use of intellectual property, technology, or research licenses. It reflects the company's commitment to pay for essential R&D assets or proprietary rights that are critical to its clinical-stage pipeline. Monitoring this balance helps investors assess the company's ongoing contractual obligations and potential cash outflows related to strategic partnerships.